Ultra-sensitive ctDNA profiling predicts responses in esophagogastric cancer
Author Information
Author(s): Nixon Andrew B., Navarro Fábio C. P., Zhou Katherine I., Abbott Charles, McDaniel Lee, Howard Lauren, Brady J Christopher, Liu Yingmiao, Jia Jingquan, Niedzwiecki Donna, Strickler John, Boyle Sean M., Chen Richard O., Uronis Hope
Primary Institution: Duke University Medical Center
Hypothesis
Can ultra-sensitive circulating tumor DNA (ctDNA) profiling predict treatment responses and disease progression in esophagogastric cancer patients?
Conclusion
The study found that ctDNA dynamics can predict treatment responses and disease progression in patients with advanced esophagogastric cancer.
Supporting Evidence
- All patients were ctDNA-positive at baseline.
- Lack of early molecular response was associated with worse overall survival.
- ctDNA dynamics correlated with changes in tumor size.
- Molecular progression was detected earlier than imaging-derived progression.
- Patients with ctDNA clearance had improved progression-free survival.
Takeaway
Doctors can use a special blood test to see how well cancer treatment is working and if the cancer is coming back, helping them make better decisions.
Methodology
The study used a tumor-informed liquid biopsy approach to analyze ctDNA in patients receiving chemotherapy and immunotherapy.
Limitations
The study was limited to a small sample size and focused on a specific patient population.
Participant Demographics
Patients with HER2-negative metastatic esophagogastric cancer.
Statistical Information
P-Value
p = 0.005
Confidence Interval
95% CI 1.8-24.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website